FRI0270 Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis (DcSSc)
BackgroundDcSSc is associated with high morbidity and mortality, and reduced quality of life. Patient priorities are rarely discussed, with physicians focusing on organ involvement. Using discursive approaches and ethnography, we evaluated the impact of dcSSc on patients' daily lives, and exami...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.532-533 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 533 |
---|---|
container_issue | Suppl 2 |
container_start_page | 532 |
container_title | Annals of the rheumatic diseases |
container_volume | 75 |
creator | Khanna, D. Allanore, Y. Denton, C. Matucci-Cerinic, M. Pope, J. Hinzmann, B. Briody, S. de Oliveira Pena, J. Distler, O. |
description | BackgroundDcSSc is associated with high morbidity and mortality, and reduced quality of life. Patient priorities are rarely discussed, with physicians focusing on organ involvement. Using discursive approaches and ethnography, we evaluated the impact of dcSSc on patients' daily lives, and examined how disease burden shapes patient outlook.MethodsPatients were recruited via healthcare professionals (HCPs) or patient associations. In France, Italy, the UK and USA, patients filmed short (∼15-minute) daily video diaries about their lives over 7 days. On Days 1 and 7, patients participated in a moderator-led discussion of their experiences, and an observation session. In Germany and Spain, patients participated in 60-minute telephone interviews. Video footage and transcribed discussions were reviewed, and the data were categorized and assessed for themes, patterns, and indicators of emotion, ambivalence, and conflict.ResultsTwenty-three patients (mean age 54 years; 83% women) participated. Of these, 17 made video diaries, and 6 took part in telephone interviews. The majority of video diaries and interviews took place in patients' homes; on average 5.25 hours of video footage were collected per patient.Results show that time to diagnosis was often delayed, as patients trivialized symptoms and HCPs attributed symptoms to other causes. Patients had a poor understanding of their diagnosis, and rarely received patient information. DcSSc patients had a high treatment burden; on average this patient sample received 10 tablets of prescribed drugs daily. Importantly, while patients were aware of the seriousness of organ involvement, they reported that skin changes, pain, and fatigue had a dominant effect on daily life, impairing their ability to perform routine tasks. Skin tightening in the lower limbs and feet lead to deformity and loss of mobility, while Raynaud's phenomenon, calcinosis, and digital ulcers caused significant pain and loss of function. Changes in appearance lead to embarrassment, social withdrawal, and depression. Patients experienced dcSSc as a series of losses, including independence and self-esteem, and the unpredictability of the disease made acceptance of the condition difficult (Figure 1). Moreover, patients tended to have small support networks and support services were not offered as part of standard care.ConclusionsPatients with dcSSc had high treatment and emotional burdens, with skin complications, pain, and fatigue profoundly affecting thei |
doi_str_mv | 10.1136/annrheumdis-2016-eular.3586 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901841926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322512437</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1276-2fcd8dabf1933a60ec78594c5b60772f749b7f2ba1df261f3a21b222c9659bd63</originalsourceid><addsrcrecordid>eNqVkLFOwzAURS0EEqXwD5a6wJBiO4kdiwlaCpWQqAisWLZjC1eNU-xk6MbCj_IlJJSBlenpXd373tUBYILRFOOUXkrvw5vp6srFhCBME9NtZJimeUEPwAhntOhlig7BCCGUJhmn7BicxLjuV1TgYgReF09LRBj6-vhcydYZ38KVCdpsW9d42Fg4d9HIaOBNFyrjofO9Ym3XK7Ould40XYTlLramdhqWemNCE12E53NdlvriFBxZuYnm7HeOwcvi9nl2nzw83i1n1w-JwoTRhFhdFZVUFvM0lRQZzYqcZzpXFDFGLMu4YpYoiStLKLapJFgRQjSnOVcVTcdgsr-7Dc17Z2Ir1k0XfP9SYI5wkWFOBtfV3qX7kjEYK7bB1TLsBEZiACr-ABUDUPEDVAxA-zTdp1W9_lfwGxTegbg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901841926</pqid></control><display><type>article</type><title>FRI0270 Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis (DcSSc)</title><source>BMJ Journals - NESLi2</source><creator>Khanna, D. ; Allanore, Y. ; Denton, C. ; Matucci-Cerinic, M. ; Pope, J. ; Hinzmann, B. ; Briody, S. ; de Oliveira Pena, J. ; Distler, O.</creator><creatorcontrib>Khanna, D. ; Allanore, Y. ; Denton, C. ; Matucci-Cerinic, M. ; Pope, J. ; Hinzmann, B. ; Briody, S. ; de Oliveira Pena, J. ; Distler, O.</creatorcontrib><description>BackgroundDcSSc is associated with high morbidity and mortality, and reduced quality of life. Patient priorities are rarely discussed, with physicians focusing on organ involvement. Using discursive approaches and ethnography, we evaluated the impact of dcSSc on patients' daily lives, and examined how disease burden shapes patient outlook.MethodsPatients were recruited via healthcare professionals (HCPs) or patient associations. In France, Italy, the UK and USA, patients filmed short (∼15-minute) daily video diaries about their lives over 7 days. On Days 1 and 7, patients participated in a moderator-led discussion of their experiences, and an observation session. In Germany and Spain, patients participated in 60-minute telephone interviews. Video footage and transcribed discussions were reviewed, and the data were categorized and assessed for themes, patterns, and indicators of emotion, ambivalence, and conflict.ResultsTwenty-three patients (mean age 54 years; 83% women) participated. Of these, 17 made video diaries, and 6 took part in telephone interviews. The majority of video diaries and interviews took place in patients' homes; on average 5.25 hours of video footage were collected per patient.Results show that time to diagnosis was often delayed, as patients trivialized symptoms and HCPs attributed symptoms to other causes. Patients had a poor understanding of their diagnosis, and rarely received patient information. DcSSc patients had a high treatment burden; on average this patient sample received 10 tablets of prescribed drugs daily. Importantly, while patients were aware of the seriousness of organ involvement, they reported that skin changes, pain, and fatigue had a dominant effect on daily life, impairing their ability to perform routine tasks. Skin tightening in the lower limbs and feet lead to deformity and loss of mobility, while Raynaud's phenomenon, calcinosis, and digital ulcers caused significant pain and loss of function. Changes in appearance lead to embarrassment, social withdrawal, and depression. Patients experienced dcSSc as a series of losses, including independence and self-esteem, and the unpredictability of the disease made acceptance of the condition difficult (Figure 1). Moreover, patients tended to have small support networks and support services were not offered as part of standard care.ConclusionsPatients with dcSSc had high treatment and emotional burdens, with skin complications, pain, and fatigue profoundly affecting their lives. Patients placed the greatest emphasis on these issues rather than the possibility of organ involvement. There is an unmet need for patient information at the time of diagnosis, and for emotional support services throughout their journey with dcSSc. Directing patients to websites such as SSc patient organizations may be helpful.Disclosure of InterestD. Khanna Grant/research support from: NIH/NIAMS, NIH/ NIAID, Bayer, BMS, Consultant for: Bayer, BMS, Genetech/Roche, GSK, Genkyotex, Sanofi-Aventis, Actelion, Gilead, Employee of: University of Michigan, Y. Allanore Grant/research support from: Bristol-Myers Squibb, Roche/Genentech, Inventiva, Pfizer, Sanofi, Servier, Consultant for: Actelion, Bayer, Roche/Genentech, Inventiva, Medac, Pfizer, Sanofi, Servier, UCB, C. Denton Grant/research support from: Actelion, GSK, Novartis, CSL Behring, Consultant for: Bayer, Roche, GSK, Actelion, Inventiva, CSL Behring, Takeda, Merck-Serono, Medimmune, Biogen, M. Matucci-Cerinic Consultant for: Actelion, GSK, Pfizer, BMS, J. Pope Grant/research support from: Actelion, Bayer, Consultant for: Actelion, Bayer, B. Hinzmann Shareholder of: Bayer Pharma AG, Employee of: Bayer Pharma AG, S. Briody: None declared, J. de Oliveira Pena Employee of: Bayer HealthCare Pharmaceuticals Inc., O. Distler Grant/research support from: Actelion, Pfizer, Sanofi-Aventis, Bayer, Consultant for: Ergonex, United BioSource, Biovitrium, Novartis, Biogen Idec, Inventiva</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.3586</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.532-533</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/75/Suppl_2/532.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/75/Suppl_2/532.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,315,782,786,3198,23578,27931,27932,77608,77639</link.rule.ids></links><search><creatorcontrib>Khanna, D.</creatorcontrib><creatorcontrib>Allanore, Y.</creatorcontrib><creatorcontrib>Denton, C.</creatorcontrib><creatorcontrib>Matucci-Cerinic, M.</creatorcontrib><creatorcontrib>Pope, J.</creatorcontrib><creatorcontrib>Hinzmann, B.</creatorcontrib><creatorcontrib>Briody, S.</creatorcontrib><creatorcontrib>de Oliveira Pena, J.</creatorcontrib><creatorcontrib>Distler, O.</creatorcontrib><title>FRI0270 Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis (DcSSc)</title><title>Annals of the rheumatic diseases</title><description>BackgroundDcSSc is associated with high morbidity and mortality, and reduced quality of life. Patient priorities are rarely discussed, with physicians focusing on organ involvement. Using discursive approaches and ethnography, we evaluated the impact of dcSSc on patients' daily lives, and examined how disease burden shapes patient outlook.MethodsPatients were recruited via healthcare professionals (HCPs) or patient associations. In France, Italy, the UK and USA, patients filmed short (∼15-minute) daily video diaries about their lives over 7 days. On Days 1 and 7, patients participated in a moderator-led discussion of their experiences, and an observation session. In Germany and Spain, patients participated in 60-minute telephone interviews. Video footage and transcribed discussions were reviewed, and the data were categorized and assessed for themes, patterns, and indicators of emotion, ambivalence, and conflict.ResultsTwenty-three patients (mean age 54 years; 83% women) participated. Of these, 17 made video diaries, and 6 took part in telephone interviews. The majority of video diaries and interviews took place in patients' homes; on average 5.25 hours of video footage were collected per patient.Results show that time to diagnosis was often delayed, as patients trivialized symptoms and HCPs attributed symptoms to other causes. Patients had a poor understanding of their diagnosis, and rarely received patient information. DcSSc patients had a high treatment burden; on average this patient sample received 10 tablets of prescribed drugs daily. Importantly, while patients were aware of the seriousness of organ involvement, they reported that skin changes, pain, and fatigue had a dominant effect on daily life, impairing their ability to perform routine tasks. Skin tightening in the lower limbs and feet lead to deformity and loss of mobility, while Raynaud's phenomenon, calcinosis, and digital ulcers caused significant pain and loss of function. Changes in appearance lead to embarrassment, social withdrawal, and depression. Patients experienced dcSSc as a series of losses, including independence and self-esteem, and the unpredictability of the disease made acceptance of the condition difficult (Figure 1). Moreover, patients tended to have small support networks and support services were not offered as part of standard care.ConclusionsPatients with dcSSc had high treatment and emotional burdens, with skin complications, pain, and fatigue profoundly affecting their lives. Patients placed the greatest emphasis on these issues rather than the possibility of organ involvement. There is an unmet need for patient information at the time of diagnosis, and for emotional support services throughout their journey with dcSSc. Directing patients to websites such as SSc patient organizations may be helpful.Disclosure of InterestD. Khanna Grant/research support from: NIH/NIAMS, NIH/ NIAID, Bayer, BMS, Consultant for: Bayer, BMS, Genetech/Roche, GSK, Genkyotex, Sanofi-Aventis, Actelion, Gilead, Employee of: University of Michigan, Y. Allanore Grant/research support from: Bristol-Myers Squibb, Roche/Genentech, Inventiva, Pfizer, Sanofi, Servier, Consultant for: Actelion, Bayer, Roche/Genentech, Inventiva, Medac, Pfizer, Sanofi, Servier, UCB, C. Denton Grant/research support from: Actelion, GSK, Novartis, CSL Behring, Consultant for: Bayer, Roche, GSK, Actelion, Inventiva, CSL Behring, Takeda, Merck-Serono, Medimmune, Biogen, M. Matucci-Cerinic Consultant for: Actelion, GSK, Pfizer, BMS, J. Pope Grant/research support from: Actelion, Bayer, Consultant for: Actelion, Bayer, B. Hinzmann Shareholder of: Bayer Pharma AG, Employee of: Bayer Pharma AG, S. Briody: None declared, J. de Oliveira Pena Employee of: Bayer HealthCare Pharmaceuticals Inc., O. Distler Grant/research support from: Actelion, Pfizer, Sanofi-Aventis, Bayer, Consultant for: Ergonex, United BioSource, Biovitrium, Novartis, Biogen Idec, Inventiva</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkLFOwzAURS0EEqXwD5a6wJBiO4kdiwlaCpWQqAisWLZjC1eNU-xk6MbCj_IlJJSBlenpXd373tUBYILRFOOUXkrvw5vp6srFhCBME9NtZJimeUEPwAhntOhlig7BCCGUJhmn7BicxLjuV1TgYgReF09LRBj6-vhcydYZ38KVCdpsW9d42Fg4d9HIaOBNFyrjofO9Ym3XK7Ould40XYTlLramdhqWemNCE12E53NdlvriFBxZuYnm7HeOwcvi9nl2nzw83i1n1w-JwoTRhFhdFZVUFvM0lRQZzYqcZzpXFDFGLMu4YpYoiStLKLapJFgRQjSnOVcVTcdgsr-7Dc17Z2Ir1k0XfP9SYI5wkWFOBtfV3qX7kjEYK7bB1TLsBEZiACr-ABUDUPEDVAxA-zTdp1W9_lfwGxTegbg</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Khanna, D.</creator><creator>Allanore, Y.</creator><creator>Denton, C.</creator><creator>Matucci-Cerinic, M.</creator><creator>Pope, J.</creator><creator>Hinzmann, B.</creator><creator>Briody, S.</creator><creator>de Oliveira Pena, J.</creator><creator>Distler, O.</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201606</creationdate><title>FRI0270 Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis (DcSSc)</title><author>Khanna, D. ; Allanore, Y. ; Denton, C. ; Matucci-Cerinic, M. ; Pope, J. ; Hinzmann, B. ; Briody, S. ; de Oliveira Pena, J. ; Distler, O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1276-2fcd8dabf1933a60ec78594c5b60772f749b7f2ba1df261f3a21b222c9659bd63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khanna, D.</creatorcontrib><creatorcontrib>Allanore, Y.</creatorcontrib><creatorcontrib>Denton, C.</creatorcontrib><creatorcontrib>Matucci-Cerinic, M.</creatorcontrib><creatorcontrib>Pope, J.</creatorcontrib><creatorcontrib>Hinzmann, B.</creatorcontrib><creatorcontrib>Briody, S.</creatorcontrib><creatorcontrib>de Oliveira Pena, J.</creatorcontrib><creatorcontrib>Distler, O.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khanna, D.</au><au>Allanore, Y.</au><au>Denton, C.</au><au>Matucci-Cerinic, M.</au><au>Pope, J.</au><au>Hinzmann, B.</au><au>Briody, S.</au><au>de Oliveira Pena, J.</au><au>Distler, O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FRI0270 Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis (DcSSc)</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06</date><risdate>2016</risdate><volume>75</volume><issue>Suppl 2</issue><spage>532</spage><epage>533</epage><pages>532-533</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundDcSSc is associated with high morbidity and mortality, and reduced quality of life. Patient priorities are rarely discussed, with physicians focusing on organ involvement. Using discursive approaches and ethnography, we evaluated the impact of dcSSc on patients' daily lives, and examined how disease burden shapes patient outlook.MethodsPatients were recruited via healthcare professionals (HCPs) or patient associations. In France, Italy, the UK and USA, patients filmed short (∼15-minute) daily video diaries about their lives over 7 days. On Days 1 and 7, patients participated in a moderator-led discussion of their experiences, and an observation session. In Germany and Spain, patients participated in 60-minute telephone interviews. Video footage and transcribed discussions were reviewed, and the data were categorized and assessed for themes, patterns, and indicators of emotion, ambivalence, and conflict.ResultsTwenty-three patients (mean age 54 years; 83% women) participated. Of these, 17 made video diaries, and 6 took part in telephone interviews. The majority of video diaries and interviews took place in patients' homes; on average 5.25 hours of video footage were collected per patient.Results show that time to diagnosis was often delayed, as patients trivialized symptoms and HCPs attributed symptoms to other causes. Patients had a poor understanding of their diagnosis, and rarely received patient information. DcSSc patients had a high treatment burden; on average this patient sample received 10 tablets of prescribed drugs daily. Importantly, while patients were aware of the seriousness of organ involvement, they reported that skin changes, pain, and fatigue had a dominant effect on daily life, impairing their ability to perform routine tasks. Skin tightening in the lower limbs and feet lead to deformity and loss of mobility, while Raynaud's phenomenon, calcinosis, and digital ulcers caused significant pain and loss of function. Changes in appearance lead to embarrassment, social withdrawal, and depression. Patients experienced dcSSc as a series of losses, including independence and self-esteem, and the unpredictability of the disease made acceptance of the condition difficult (Figure 1). Moreover, patients tended to have small support networks and support services were not offered as part of standard care.ConclusionsPatients with dcSSc had high treatment and emotional burdens, with skin complications, pain, and fatigue profoundly affecting their lives. Patients placed the greatest emphasis on these issues rather than the possibility of organ involvement. There is an unmet need for patient information at the time of diagnosis, and for emotional support services throughout their journey with dcSSc. Directing patients to websites such as SSc patient organizations may be helpful.Disclosure of InterestD. Khanna Grant/research support from: NIH/NIAMS, NIH/ NIAID, Bayer, BMS, Consultant for: Bayer, BMS, Genetech/Roche, GSK, Genkyotex, Sanofi-Aventis, Actelion, Gilead, Employee of: University of Michigan, Y. Allanore Grant/research support from: Bristol-Myers Squibb, Roche/Genentech, Inventiva, Pfizer, Sanofi, Servier, Consultant for: Actelion, Bayer, Roche/Genentech, Inventiva, Medac, Pfizer, Sanofi, Servier, UCB, C. Denton Grant/research support from: Actelion, GSK, Novartis, CSL Behring, Consultant for: Bayer, Roche, GSK, Actelion, Inventiva, CSL Behring, Takeda, Merck-Serono, Medimmune, Biogen, M. Matucci-Cerinic Consultant for: Actelion, GSK, Pfizer, BMS, J. Pope Grant/research support from: Actelion, Bayer, Consultant for: Actelion, Bayer, B. Hinzmann Shareholder of: Bayer Pharma AG, Employee of: Bayer Pharma AG, S. Briody: None declared, J. de Oliveira Pena Employee of: Bayer HealthCare Pharmaceuticals Inc., O. Distler Grant/research support from: Actelion, Pfizer, Sanofi-Aventis, Bayer, Consultant for: Ergonex, United BioSource, Biovitrium, Novartis, Biogen Idec, Inventiva</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/annrheumdis-2016-eular.3586</doi><tpages>2</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.532-533 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_journals_1901841926 |
source | BMJ Journals - NESLi2 |
title | FRI0270 Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis (DcSSc) |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T12%3A15%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FRI0270%E2%80%85Patient%20Perception%20of%20Disease%20Burden%20in%20Diffuse%20Cutaneous%20Systemic%20Sclerosis%20(DcSSc)&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Khanna,%20D.&rft.date=2016-06&rft.volume=75&rft.issue=Suppl%202&rft.spage=532&rft.epage=533&rft.pages=532-533&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.3586&rft_dat=%3Cproquest_cross%3E4322512437%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901841926&rft_id=info:pmid/&rfr_iscdi=true |